
    
      The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to
      Week 48 and every 8 weeks after Week 48. All subjects will continue treatment until the last
      subject in the study reaches 48 weeks in the study. At least 30% of subjects randomized
      should have baseline MELD score ≥15 and ≤20.

      For each subject, the study will consist of:

        -  Screening period of up to 4 weeks

        -  Randomized, double-blind treatment period of at least 48 weeks

        -  A follow-up visit 2 weeks after completion of study drug treatment

      The duration of each subject's participation will be at least 54 weeks for those completing
      the entire study.
    
  